OAOvadia Abulafia

Ovadia Abulafia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ovadia Abulafia has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early First-Trimester Transvaginal Sonographic Diagnosis of Maternal Ureterocele

    by David M. Sherer, Mudar Dalloul, Andrew Athanassiou, Ivrose Joseph, Stephanie Grube, Ovadia Abulafia

  • Sonographic depiction of non-palpable uterine papillary serous carcinoma metastasis embedded within the abdominal wall

    by David M. Sherer, Albert Palileo, Sanche Graham, Andrew Athanassiou, Jordan Hamilton, Ovadia Abulafia

    • 1 January 2015
      • Vol. 45  (6) , 650-8

    Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.

    by Ehsan Sarafraz-Yazdi, Constantine Gorelick, Allison R Wagreich, Ghadir Salame, Mallorie Angert, Charles H Gartman, Vinita Gupta, Wilbur B Bowne, Yi-Chun Lee, Ovadia Abulafia, et al.

    Despite an 80% response rate to chemotherapy, epithelial ovarian cancer has the highest case fatality rate of all gynecologic malignancies. Several studies have shown the efficiency of anticancer peptides PNC-27 and PNC-28 in killing a variety of cancer cells selectively in vitro and in vivo. The purpose of this study was to evaluate the efficacy of PNC-27 against human primary epithelial ovarian cancer. We established primary cultures of freshly isolated epithelial ovarian cancer cells from patients with newly diagnosed ovarian cystadenocarcinomas. Two cell lines were obtained, one from mucinous cystadenocarcinoma, and the other from high-grade papillary serous carcinoma. The cancerous properties of these cells were characterized in vitro morphologically, by their growth requirements and serum independence. Treatment effects with PNC-27 were followed qualitatively by light microscopy, and quantitatively by measuring inhibition of cell growth using the MTT cell proliferation assay and direct cytotoxicity by measuring lactate dehydrogenase (LDH). PNC-27 inhibits in a dose-dependent manner the growth of and is cytotoxic to human primary cancer cells that had been freshly isolated from two ovarian epithelial cancers. The results further show that the control peptide PNC-29 has no effect on the primary cancer cells. Our results also show that PNC-27 is cytotoxic to cells from long-established and chemotherapy-resistant human ovarian cancer cell lines. These findings show, for the first time, the efficacy of PNC-27 on freshly isolated, primary human cancer cells. Our results indicate the potential of PNC-27 peptide as an efficient alternative treatment of previously untreated ovarian cancer as well as for ovarian cancers that have become resistant to present chemotherapies.


  • Open Access

    Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

    by Charles Kunos, Tomas Radivoyevitch, Fadi W Abdul-Karim, James Fanning, Ovadia Abulafia, Albert J Bonebrake, Lydia Usha

    The potent ribonucleotide reductase (RNR) inhibitor 3-aminopyridine-2-carboxyaldehyde-thiosemicarbazone (3-AP) was tested as a chemosensitizer for restored cisplatin-mediated cytotoxicity in platinum-resistant ovarian cancer.


  • Determination of Urinary Cortisol Metabolites in Spot Urine of Patients with Uterine Cancer Utilizing Segmental GC/MS/MS

    by Vijaya L Nacharaju, Yi-Chun Lee, Ghadir Salame, Tana Shah, Erin Stevens, Katherine Economos, Constantine Gorelick, Ozgul Muneyyirci-Delale, Ovadia Abulafia

    Urinary cortisol metabolites were studied intensively by several investigators using GC/MS method of analysis. In general 24-hour urine collection is used for steroid analysis. Measuring cortisol metabolites, especially urinary free cortisol in spot urine is difficult due to dilution effect. We developed a method using segmental GC/MS/MS analysis to achieve this goal. We previously described 11β-HSD enzyme activity in endometrial cancer (Manolis et al, Gynecol Obstet Invest, 2006). The ability to analyze cortisol metabolites in spot urine may provide valuable metabolic information in this disease. Spot urines samples from 14 patients with endometrial cancer were analyzed. Steroid conjugates were extracted from 5 ml of spot urine using C-18 columns and subjected to hydrolysis by glucoronidase enzyme for 48 hours at 37° C. Steroids were re-extracted after hydrolysis by C-18 columns. The free steroids were derivatized to Methoxime-trimethylsilyl derivatives and one µl of this mixture was injected into varian 2200 GC/MS instrument using auto-injector. Based on EI/MS mass spectra, conditions were determined to achieve optimal sensitivity by MS/MS isolation and collision induced dissociation of the molecular ion. The steroid metabolites of interest were determined in two consecutive injections. First injection was made to determine internal standard diethyl stilbestrol (DES) in a segment 4-15 minutes, THF and allo-THF in a segment 15-18 minutes and free cortisol in a segment between 18 to 25.5 minutes. The second consecutive injection was made to determine DES as above and THE in a segment 15-18 and free cortisone in a segment 18-25.5. Appropriate excitation storage levels were chosen for each segment based on parent molecular weight. The separation of interested steroids was achieved by using 2° C/min temperature increments between 250° C and 290° C. A method using segmental GC/MS/MS was developed to analyze cortisol metabolites from spot urine. We were able to measure free cortisol in all 14 specimens. The two consecutive injections facilitate determination of THE and THF levels without interference, as these compounds elute closely. This ratio of (THF + allo-THF)/THE in spot urine specimens of patients with endometrial carcinoma was 1.11± 1.21 (mean ± SD). Our data suggest that the ability to determine free cortisol levels in spot urine may assist in understanding cortisol metabolism in patients with gynecologic malignancies. Nothing to Disclose: VLN, Y-CL, GS, TS, ES, KE, CG, OM-D, OA

  • Cortisol Metabolism in Patients with Benign and Malignant Uterine Tumors: Urinary Steroid Analysis Utilizing GC/MS/MS

    by Ovadia Abulafia, Yi-Chun Lee, Ghadir Salame, Tana Shah, Erin Stevens, Katherine Economos, Constantine Gorelick, Ozgul Muneyyirci-Delale, Vijaya L Nacharaju

    The role of glucocorticoids in reproductive physiology was suggested by several investigators. The levels of active steroid cortisol are maintained by the conversion of cortisol (F) to cortisone (E) by 11β-Hydroxysteroid dehydrogenase (11β-HSD) or by converting into tetrahydrocortisol (THF) isomers (THF and alloTHF) in the liver with subsequent renal excretion. Measurements of urinary steroid levels of free cortisol, THF and THE enhance knowledge of cortisol metabolism. The ratio (THF + allo-THF)/THE represents 11β-HSD function and the ratio F/(THF + allo-THF) represents hepatic clearance of free cortisol. We developed a GC/MS/MS method to determine these ratios in spot urine samples. Following approval by Institutional Review Board, spot urine specimens were collected from normal controls (n=14) and women with either uterine leiomyomata (n=10) or endometrial cancer (n=14) and kept frozen at −80o C. Urinary steroids were extracted using C-18 columns, hydrolyzed with glucoronidase enzyme, re-extracted, derivatized to yield MO-TMS (methoxime-trimethylsilyl) derivatives. A segmental GC/MS/MS method was developed to quantify THF, allo-THF and free cortisol in first injection and THE and free cortisone in second injection. The injections were made consecutively. The THE, THF, allo THF and cortisol peaks were identified in all samples, whereas cortisone peak was not identified in all samples. The ratios (THF+allo-THF)/THE, F/(THF+allo-THF) were calculated and compared among control and study subjects. The (THF + allo-THF)/THE ratios (mean ± SD) in controls, leiomyoma and endometrial tumors were 1.01 ± 0.57, 0.70 ± 0.13 and 1.11 ± 1.21, respectively. The F/(THF + allo-THF) ratios were 0.14 ± 0.08, 0.16 ± 0.21 and 0.50 ± 0.59, respectively. The F/(THF + allo-THF) ratios were higher in endometrial cancer patients when compared to normal controls the p = 0.032, and (THF+allo-THF)/THE ratio was not different. All ratios in leiomyomata were not different from normal controls. Our results indicate higher levels of free cortisol in urine samples of patients with endometrial cancer in comparison with normal controls indicating decreased hepatic conversion of free cortisol to tetrahydrocortisol. Nothing to Disclose: OA, Y-CL, GS, TS, ES, KE, CG, OM-D, VLN

  • Open Access

    Sonographic Features Associated With Post-Uterine Artery Embolization Pyomyoma

    by Ovadia Abulafia, Tana Shah, Ghadir Salame, Michelle J. Miller, Eli Serur, Harry L. Zinn, Margarita Sokolovski, David M. Sherer


    • 1 May 2009
      • Vol. 54  (5) , 325-6

    Advanced ovarian carcinoma following bilateral uterine artery embolization: a case report.

    by Allison Wagreich, Ghadir Salame, Yi-Chun Lee, Ovadia Abulafia

    Bilateral uterine artery embolization has become an accepted therapeutic modality in the management of patients with symptomatic uterine leiomyomata. Complications of bilateral uterine artery embolization, including rare cases of malignancies, have been reported following this procedure. We present a 46-year-old woman, gravida 3, para 1, who was treated with bilateral uterine artery embolization for symptomatic uterine leiomyomata following pelvic sonography and magnetic resonance imaging, which depicted bilateral normal adnexa. Nine months after the procedure she was diagnosed with stage III ovarian carcinoma. Patients undergoing bilateral uterine artery embolization should be informed of the possibility of preexisting or potential subsequent development of ovarian carcinoma, reflecting the lack of an effective screening method for this disease.


  • Sulfatase Activity in Normal and Neoplastic Endometrium

    by Ovadia Abulafia, Yi-Chun Lee, Alison Wagreich, Kathy Economos, Eli Serur, Vijaya L. Nacharaju

    Background: Dehydroepiandrosterone sulfate (DHEAS) is metabolized to active androgens and estrogens, which may have a role in the development of endometrial cancer. Methods: We studied DHEAS conversion to dehydroepiandrosterone (DHEA) in normal and neoplastic endometrium utilizing gas chromatography-mass spectral (GC-MS) analysis. Endometrial homogenate was incubated with known amounts of DHEAS for 4 h at 37°C. Methanol extract was separated from debris by centrifugation, concentrated to 200 μl and 1 μl injected into the GC-MS instrument, equipped with a CP-Sil 8 column. DHEAS and DHEA areas were calculated by autoquantization and DHEA/DHEAS ratio was used for comparing sulfatase activity among normal endometrium (n = 6), Stage I endometrioid carcinoma (EC) (n = 15), Stage I mixed mesodermal Müllerian tumor (MMMT) (n = 6) and Stage I uterine papillary serous carcinoma (UPSC) (n = 7). Results: DHEA/DHEAS ratios in normal endometrium, EC, MMMT and UPSC were 1.45 ± 1.10, 5.63 ± 3.27, 2.88 ± 0.99, and 3.04 ± 1.76, respectively. Sulfatase activity was significantly higher in EC when compared with normal endometrium (p < 0.001), MMMT (p < 0.05), and UPSC (p < 0.05). The enzyme activity did not differ significantly between low-grade and high-grade EC tumors (5.8 ± 2.77 and 5.49 ± 3.84, respectively, p > 0.05). Conclusion: Stage I EC have higher sulfatase activity than normal endometrium, and Stage I MMMT and UPSC tumors.


  • Type 2 11β-hydroxysteroid dehydrogenase activity in human ovarian cancer

    by Sarah Temkin, Vijaya L. Nacharaju, Mira Hellman, Yi-Chun Lee, Ovadia Abulafia